Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% lacking actionable PD-L1 eligibility and historically limited to ...

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know ...

Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about ...

Identification of fibroids on ultrasound can prematurely close evaluation, despite frequent co-existence and a ...

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver ...

Training deficits in STS brachytherapy stem primarily from limited resident case exposure, despite broad perceived importance ...

Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that ...

Reproductive-care access remains unsettled as mifepristone telehealth/mail distribution is temporarily protected by the ...

The heart failure (HF) treatment landscape continues to evolve rapidly in 2026, with emerging evidence pointing toward a ...

USPSTF recommendations have statutory coverage implications under the ACA, mandating no-cost coverage for graded preventive services and directly shaping access to mammography, colorectal screening, ...

In an interview with The American Journal of Managed Care ® (AJMC ®) at the American Thoracic Society International ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...